Pneumonia recovery reprograms the alveolar macrophage pool

Guillon, Antoine; Arafa, E.I.; Barker, Kimberly A.; Belkina, Anna C.; Martin, I.M.C.; Shenoy, A.T.; Wooten, Alicia K; Ana, C. Lyon De; Dai, Anqi; Labadorf, Adam; Escalante, Jaileene Hernandez; Dooms, Hans; Blasco, Hélène; Traber, K.; Jones, Matthew R.; Quinton, Lee J.; Mizgerd, Joseph P.

doi:10.1172/jci.insight.133042

Cited by 43 publications

(62 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Effects of resolved pneumococcal pneumonias on circulating cells and antibodies. Resolution of pneumococcal pneumonias in mice provides serotype-independent lung protection against subsequent pneumonia conferred in part by CD4 + TRM cells and remodeled alveolar macrophages (23)(24)(25). We suspected that additional immune changes elicited by pneumococcal exposures remained to be identified.…”

Section: Resultsmentioning

confidence: 99%

Lung-resident memory B cells protect against bacterial pneumonia

Barker¹,

Etesami²,

Shenoy³

et al. 2021

Journal of Clinical Investigation

Self Cite

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Lung-resident memory B cells protect against bacterial pneumonia

Barker¹,

Etesami²,

Shenoy³

et al. 2021

Journal of Clinical Investigation

Self Cite

View full text Add to dashboard Cite

“…Furthermore, other pathogens can also induce trained immunity. For example, S. pneumoniae infection was shown to cause long‐term phenotypic changes, including decreased expression of SiglecF and increased expression of MHCII, CD64 and CD11c in murine alveolar macrophages as well as metabolomic changes, with increased phosphocreatine and creatine production in trained cells that resulted in enhanced responsiveness and clearance of secondary bacterial infections (Guillon et al, 2020). Alveolar macrophages from S. pneumoniae ‐colonised individuals also displayed functional changes with increased opsonophagocytic activity and nonspecific protection against subsequent ex vivo challenges with Streptococcus pyogenes and S. aureus compared to AM from individuals not colonised with S. pneumoniae (Mitsi et al, 2020).…”

Section: Innate Immune Memorymentioning

confidence: 99%

“…Trained AM to S. pneumoniae alone show increases in SiglecF and decreased MHCII along with increased in metabolites such as phosphocreatine. AM trained to S. pneumoniae had enhanced signalling upon re‐infection, with increases in genes associated with immune signalling and energy production (Guillon et al, 2020). Therefore, different training agents could have distinct effects on specific cells types.…”

Section: Trained Immunity Across Cell Types and Tissuesmentioning

confidence: 99%

Trained immunity and host‐pathogen interactions

Peignier

Parker

2020

Cellular Microbiology

View full text Add to dashboard Cite

Infectious diseases are a leading cause of death worldwide with over 8 million fatalities accounted for in 2016. Solicitation of host immune defenses by vaccination is the treatment of choice to prevent these infections. It has long been thought that vaccine immunity was solely mediated by the adaptive immune system. However, over the past decade, numerous studies have shown that innate immune cells can also retain memory of these encounters. This process, called innate immune memory, is mediated by metabolic and epigenetic changes that make cells either hyperresponsive (trained immunity) or hyporesponsive (tolerance) to subsequent challenges. In this review, we discuss the concepts of trained immunity and tolerance in the context of host‐pathogen interactions.

show abstract

“…Although it remains to be understood how to best harness trained immunity for COVID-19 vaccine strategies, recent evidence suggests that routes of microbial exposure or vaccination determine the tissue distribution of trained immunity 83 , 84 , 169 . As respiratory mucosal immunity is key to early clearance of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), inducing trained immunity in alveolar macrophages and other innate cells 83 , 179 – 181 through respiratory mucosal vaccination could be an effective strategy. Indeed, a human serotype 5 adenovirus-vectored vaccine delivered to the respiratory mucosa induces memory alveolar macrophages capable of trained immunity against heterologous infections 85 .…”

mentioning

confidence: 99%

Immunological considerations for COVID-19 vaccine strategies

et al. 2020

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID-19) outbreak was first reported in Wuhan, China, in late 2019 and, at the time of writing this article, has since spread to 216 countries and territories 1. It has brought the world to a standstill. The respiratory viral pathogen severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected at least 20.1 million individuals and killed more than 737,000 people globally, and counting 1. Although physical-distancing a n d o t h er t r a n s m i ss i o n-m i tigation s t r a t e g ies i m p l e m e nted in most countries during the current pandemic have prevented most citizens from being infected, these strategies will paradoxically leave them without immunity to SARS-CoV-2 and thus susceptible to additional waves of infection. Health-care workers, seniors and those with underlying health conditions are at particularly high risk 2-4. It is widely accepted that the world will not return to its prepandemic normalcy until safe and effective vaccines become available and a global vaccination programme is successfully implemented 5. As COVID-19 is new to humankind and the nature of protective immune responses is poorly understood, it is unclear which vaccine strategies will be most successful. Therefore, it is imperative to develop various vaccine platforms and strategies in parallel. Indeed, since the outbreak began, researchers around the world have been racing to develop COVID-19 vaccines, with at least 166 vaccine candidates currently in preclinical and clinical development 5 (Fig. 1). To meet the urgent need for a vaccine, a new pandemic vaccine development paradigm has been proposed that compresses the development timeline from 10-15 years to 1-2 years 6. However, there remains a lack of clarity as to what may

show abstract

Pneumonia recovery reprograms the alveolar macrophage pool

Cited by 43 publications

References 48 publications

Lung-resident memory B cells protect against bacterial pneumonia

Lung-resident memory B cells protect against bacterial pneumonia

Trained immunity and host‐pathogen interactions

Immunological considerations for COVID-19 vaccine strategies

Contact Info

Product

Resources

About